Volume 4.50 | Dec 20

Cord Blood News 4.50 December 20, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Three-Dimensional Cell Aggregates Composed of HUVECs and cbMSCs for Therapeutic Neovascularization in a Mouse Model of Hindlimb Ischemia
Three-dimensional (3D) cell aggregates composed of human umbilical vein endothelial cells (HUVECs) and cord-blood mesenchymal stem cells (cbMSCs) were used for therapeutic neovascularization to rescue tissues from critical limb ischemia. The experimental results confirmed that the transplanted 3D HUVEC/cbMSC aggregates enhanced functional vessel formation within the ischemic limb and protected it from degeneration. [Biomaterials] Abstract

New StemSpan(TM) SFEM II - for optimal CD34+ cell expansion of bone marrow and cord blood cells
PUBLICATIONS (Ranked by impact factor of the journal)

New Autoimmune Diseases after Cord Blood Transplantation: A Retrospective Study of EUROCORD and the Autoimmune Disease Working Party of EBMT
To describe incidence, risk factors and treatment of autoimmune diseases (AD) occurring after cord blood transplantation (CBT), researchers analyzed CBT recipients reported to EUROCORD having developed at least one new AD and those having not. [Blood] Abstract

Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematological Malignancies
Researchers assessed the safety and efficacy of cord blood transplantation performed precisely according to the transplant procedures of the Institute of Medical Science, University of Tokyo. [Biol Blood Marrow Transplant] Abstract

Transplant-Related Mortality, Graft Failure and Survival following Reduced Toxicity Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation in 100 Consecutive Pediatric Recipients
Myeloablative conditioning and AlloHSCT is associated with a 10-40% risk of day +100 transplant-related mortality. The authors evaluated the feasibility and safety of reduced toxicity conditioning and AlloHSCT in 100 consecutive children and adolescent recipients. [Biol Blood Marrow Transplant] Abstract

Double Umbilical Cord Blood Transplantation in Patients with Hematologic Malignancies Using a Reduced-Intensity Preparative Regimen without Antithymocyte Globulin
Researchers report the results of a non-antithymocyte globulin-containing reduced-intensity conditioning regimen, where patients received 2 Gy TBI unless they were considered to be at higher risk of graft failure, in which case they received 3 Gy of TBI. Thirty patients underwent cord blood transplants using this protocol for high-risk hematological malignancies. [Bone Marrow Transplant] Abstract

Mesenchymal Stem Cells Support Proliferation and Terminal Differentiation of B Cells
The effect of human umbilical cord mesenchymal stem cells (MSC) on proliferation and differentiation of B-cells were characterized in vitro, and researchers also tested the immunoregulatory properties of mouse bone marrow MSC on T cell dependent and independent antibody production in vivo in mice. [Cell Physiol Biochem] Abstract | Full Article

Effects of Telomerase Activity and Apoptosis on Ex Vivo Expansion of Cord Blood CD34+ Cells
Change in telomerase activity and level of apoptosis in cord blood CD34+ cells were evaluated together with specific cell population growth rate during ex vivo culture. [Cell Prolif] Abstract

The Allogeneic Umbilical Cord Mesenchymal Stem Cells Regulate the Function of T Helper 17 Cells from Patients with Rheumatoid Arthritis in an In Vitro Co-Culture System
To investigate the immunoregulatory effect of stem cell transplantation, human umbilical cord mesenchymal stem cells were co-cultured with peripheral blood mononuclear cells from patients with rheumatoid arthritis. [BMC Musculoskelet Disord] Abstract | Full Article

A Novel Filtration Method for Cord Blood Processing Using a Polyester Fabric Filter
Investigators developed a novel filtration system using a nonchemical-coated and nonwoven polyester fabric filter, which traps cells through affinity and does not require centrifugation or potentially toxic chemicals. Cell processing with the device resulted in minimum cell loss of total cells and CD34+ cells, without impairing the ability of CD34+ cells to engraft and differentiate both in vivo and in vitro. [Int J Lab Hematol] Abstract

Complimentary Wallchart: Human Hematopoietic Progenitors. Request Your Copy Today.


California Stem Cell Agency Awards $12 Million in Grants to UCSF Physician Scientists
The California Institute for Regenerative Medicine has awarded $12 million in stem cell research grants to fund four projects at The University of California, San Francisco (UCSF), part of a total $36 million in new awards to young researchers announced by the state agency. Two of the UCSF research projects focus on the blood; one focuses on muscle; and one on the intestines. All are aimed at finding better ways to regenerate healthy tissue. [The University of California, San Francisco] Press Release

New Facility Will Bridge Research and Stem Cell Therapies
The University of Rochester Medical Center has opened the doors on a new facility that will enable researchers to create, study, and ultimately use stem cells and their offspring in early-phase experimental human therapies. The Upstate Stem Cell cGMP Facility was created with $3.5 million in support from the Empire State Stem Cell Board. [University of Rochester Medical Center] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW CiRA International Symposium 2013: Raising the Next Generation of Stem Cell Research
March 11-12, 2013
Kyoto, Japan

NEW 2013 International Cord Blood Symposium
June 6-8, 2013
San Francisco, United States

View our events page to see a complete list of events in the cord blood community.


Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Postdoctoral Research Scientist – Regenerative Stem Cell Research (Oxford NHS Blood and Transplant)

Part-Time Postdoctoral Research Scientist – Regenerative Stem Cell Research (Oxford NHS Blood and Transplant)

Research Technologist – Stem Cells and Cancer (Massachusetts General Hospital & Harvard Medical School)

Postdoctoral Position (University of Iowa College of Medicine)

Postdoctoral Research Associate (Washington University in St Louis – School Of Medicine)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us